Slaughter and May is advising Shire plc on a recommended offer by Takeda Pharmaceutical Company Limited
Slaughter and May is advising Shire plc (Shire) on a recommended offer by Takeda Pharmaceutical Company Limited (Takeda) for the entire issued and to be issued ordinary share capital of Shire (the Proposed Transaction). The Proposed Transaction was announced on 8 May 2018.
Under the terms of the Proposed Transaction, Shire shareholders will be entitled to receive cash and shares in Takeda. The Proposed Transaction values Shire's entire issued and to be issued ordinary share capital at approximately £46 billion and, upon completion, will result in Shire shareholders owning approximately 50 per cent. of Takeda.
The Proposed Transaction is intended to be implemented by way of a court-sanctioned scheme of arrangement and is conditional on various matters, including shareholder approval and certain competition clearances. It is expected that the Proposed Transaction will complete in the first half of 2019.
Shire is a London listed specialty biopharmaceutical company and a constituent of the FTSE 100 Index. The company is headquartered in Dublin, Ireland, and has offices in over 60 countries.
Davis Polk & Wardwell LLP, Nagashima Ohno & Tsunematsu and Mourant Ozannes are advising Shire on US, Japanese and Jersey law matters respectively.
21 March 2019 - This transaction won an Asia Legal Award for M&A Deal of the Year: North Asia at the Asia Legal Awards 2019